Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2015-09-30
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections
NCT02801383
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
NCT01824992
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
NCT06756269
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
NCT06454175
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05584332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
Recombinant Human Interferon a-2b Gel
Plcaebo
subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant Human Interferon a-2b Gel
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High-risk HPV 16 and/or 18 positive
* Agree to sign ICF
Exclusion Criteria
* Combined with a severe fungal, trichomonas vaginitis;
* Severe primary diseases associated with cardiovascular, liver, kidney and hematopoietic system;
* Allergies or allergy to the drug known ingredients.
* Within 30 days to accept other clinical trials of drugs or are participating in clinical trials;
* Pregnant and lactating women and to be pregnant women;
* The researchers do not consider it appropriate clinical trials.
25 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lee's Pharmaceutical Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Jian Zhao, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jian Zhao, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Zhaoke-1504-Yallaferon
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.